These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 37077908)

  • 1. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
    Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
    Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1
    Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
    Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics.
    Xu P; Chen YJ; Chen H; Zhu XY; Song HF; Cao LJ; Wang XF
    Gut Liver; 2014 Mar; 8(2):186-95. PubMed ID: 24672661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
    Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
    Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM3 gene polymorphisms in patients with chronic hepatitis B virus infection: impact on disease susceptibility and hepatocellular carcinoma traits.
    Li Z; Liu Z; Zhang G; Han Q; Li N; Zhu Q; Lv Y; Chen J; Xing F; Wang Y; Li F
    Tissue Antigens; 2012 Aug; 80(2):151-7. PubMed ID: 22587604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
    Zhang Q; Yang L; Liu S; Zhang M; Jin Z
    Front Immunol; 2021; 12():645835. PubMed ID: 34177894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma.
    He J; Miao R; Chen Y; Wang H; Liu M
    Immunology; 2024 Apr; 171(4):445-463. PubMed ID: 38093705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma.
    Bai Q; Li R; He X; Hong X; Yan Y; Zhao Z; Lin H; Tacke F; Engelmann C; Hu T
    Front Immunol; 2023; 14():1320414. PubMed ID: 38116005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review.
    Allahmoradi E; Mohammadi R; Kheirandish Zarandi P; Alavian SM; Heiat M
    Expert Rev Clin Immunol; 2023 Jun; 19(6):671-688. PubMed ID: 37013795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
    Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
    J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIM-3 as a marker of exhaustion in CD8
    Mohammadizad H; Shahbazi M; Hasanjani Roushan MR; Soltanzadeh-Yamchi M; Mohammadnia-Afrouzi M
    Microb Pathog; 2019 Mar; 128():323-328. PubMed ID: 30660734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC.
    Yan F; Zhu B; Shi K; Zhang Y; Zeng X; Zhang Q; Yang Z; Wang X
    Cancer Sci; 2024 Aug; 115(8):2553-2564. PubMed ID: 38877825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma.
    Xing T; Li L; Rao X; Zhao J; Chen Y; Ju G; Xu Y; Gao X; Dong G; Xia X; Guan Y; Zhang L; Wen Z; Liang J
    BMC Gastroenterol; 2024 Jan; 24(1):11. PubMed ID: 38166741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection.
    Gu S; Fu X; Ye G; Chen C; Li X; Zhong S; Tang L; Chen H; Jiang D; Hou J; Li Y
    Front Immunol; 2021; 12():649197. PubMed ID: 34234772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.